Tribbles pseudokinase-3 (TRIB3) has been proposed to act as an inhibitor of AKT although the precise molecular basis of this activity and whether the loss of TRIB3 contributes to cancer initiation and progression remain to be clarified. In this study, by using a wide array of in vitro and in vivo approaches, including a Trib3 knockout mouse, we demonstrate that TRIB3 has a tumorsuppressing role. We also find that the mechanism by which TRIB3 loss enhances tumorigenesis relies on the dysregulation of the phosphorylation of AKT by the mTORC2 complex, which leads to an enhanced phosphorylation of AKT on Ser473 and the subsequent hyperphosphorylation and inactivation of the transcription factor FOXO3. These observations support the notion that loss of TRIB3 is associated with a more aggressive phenotype in various types of tumors by enhancing the activity of the mTORC2/AKT/FOXO axis.
Pseudokinases constitute a group of proteins that have a kinase-like domain that lacks at least one of the conserved catalytic residues.
1,2 Different studies have shown that some pseudokinases can exhibit low levels of kinase activity, while others have critical roles as activators of their specific targets. 1, 2 Moreover, aberrant regulation of pseudokinases has been implicated in the etiology and progression of a variety of diseases, including cancer. 3 The Tribbles family of pseudokinases was first described in Drosophila as a negative regulator of cell division in early embryogenesis. [4] [5] [6] [7] There are three mammalian Tribbles isoforms (Trib1, Trib2 and Trib3), homologs to the Drosophila tribbles proteins, and they all share a highly conserved central kinase-like domain, which lacks catalytic residues, and a 'tribbles specific' C-terminal domain, which has been proposed to participate in the binding to different Tribbles partners. 8 Tribbles pseudokinase-3 (TRIB3; also named TRB3, NIPK and SKIP3) has been proposed to interact with several proteins, including the transcription factors activating transcription factor 4 (ATF-4) and CHOP 9 as well as with several MAPKs. 10 TRIB3 has also been shown to interact and inhibit AKT, 11 which has been suggested to suppress insulin signaling. 11, 12 In addition, administration of different anticancer agents promotes cancer cell death via TRIB3 upregulation and the subsequent inhibition of Akt. [13] [14] [15] [16] [17] [18] [19] However, the precise molecular basis of the regulation of Akt by TRIB3 and whether loss of this pseudokinase may contribute to cancer initiation and progression remains to be clarified.
In this study, we investigated the effect of the genetic inactivation of TRIB3 in several cellular and animal models of cancer. Our findings indicate that genetic inhibition of TRIB3 enhances tumorigenesis and that this effect is due -at least primarily -to a selective inactivation of the transcription factor FOXO by the mammalian target of rapamycin complex 2 (mTORC2)/AKT axis.
Results
Genetic inhibition of TRIB3 facilitates oncogene transformation and enhances the tumorigenicity of cancer cells. Next, we generated Ras V12 /E1A-transformed MEFs as a cellular model to conduct additional mechanistic studies on the role of TRIB3 in cancer. In line with the aforementioned results, a higher percentage of Ras V12 /E1A-transformed Trib3-deficient MEFs were positive for Ki67, a marker expressed specifically in dividing cells, when compared with their corresponding WT counterparts ( Figure 1c ). Likewise, Ras V12 /E1A-transformed Trib3 À / À MEFs formed four times the number of colonies in soft agar ( Figure 1d ) as their corresponding WT MEFs. Moreover, this behavior was abolished by re-expressing an HA-tagged form of TRIB3 in Trib3-deficient cells (Figures 1c and d) , which strongly supports that the enhanced tumorigenic features of Trib3-deficient cells rely solely on the inactivation of this pseudokinase. Furthermore, the onset of tumor xenografts generated by subcutaneous injection of Trib3-deficient Ras V12 /E1A-transformed MEFs in the flank of nude mice was remarkably accelerated compared with that of tumors generated with their WT counterparts (Figure 1e ).
Of note, TRIB3 is focally deleted in tumors of epithelial origin and in breast cancer patients (tumorscape data set; Supplementary Table SI) . In addition, analysis of gene expression profiles of cancer patients from published studies reveals that TRIB3 mRNA levels are downregulated in different tumor types (Supplementary Tables SII and SIII) . Therefore we next investigated the effect of the genetic inhibition of TRIB3 in human cancer cell lines. In line with the results obtained with Trib3-deficient MEFs, knockdown of TRIB3 strongly enhanced the ability to form colonies in soft agar of breast carcinoma (BT474) and hepatocellular carcinoma (HepG2) cells lines (Figure 2a) . Moreover, TRIB3 silencing increased the number of BT474 and HepG2 cells obtained after several days in culture (Supplementary Figures  S2a-b) . Furthermore, stable silencing of TRIB3 both accelerated tumor onset and enhanced the rate of tumor growth of xenografts generated with BT474 cells (Figure 2b ) and accelerated the onset of HepG2 cell-generated tumors (Figure 2c ). Taken together, these observations strongly support that loss of TRIB3 enhances the tumorigenic capacity of different types of cancer cells.
Genetic deletion of Trib3 accelerates the progression of mouse skin papillomas to a more aggressive phenotype. As a first approach to investigate the role of TRIB3 in the control of cancer progression, we analyzed the expression of this pseudokinase in several mouse skin carcinoma cell lines exhibiting different degrees of differentiation and aggressiveness. Specifically, we studied the expression of Trib3 in the MSC11B9/MSC11A5 and CarC-R/CarC cell lines, as they constitute homogenous cellular systems of malignant progression (MSC11B9 and MSC11A5 cells were derived, respectively, from the squamous component and the more undifferentiated region of the same carcinoma; 20 and CarC-R is a minority population of less aggressive epithelial cells isolated from the fusocellular carcinoma cell line CarC. 21 ). Trib3 expression was much lower in MSC11A5 and CarC cells than in their corresponding more differentiated counterparts (Figure 3a) . Likewise, Trib3 levels were lower in the spindle cell carcinoma cell line CarB when compared with those of PDV cells (derived from a squamous cell carcinoma cell line) (Figure 3a) . Moreover, comparison of Trib3 mRNA levels of normal skin, papillomas and skin carcinomas from mice revealed that Trib3 expression correlated inversely with the aggressiveness of the lesion (Figure 3b ). These observations support that downregulation of Trib3 expression is associated with a more aggressive phenotype in mouse epithelial skin carcinomas.
Based on these observations, we therefore next investigated the effect of Trib3 genetic inactivation on the progression of the lesions observed in mice subjected to the two-stage skin carcinogenesis model as this is one of the best established paradigms for studying the mechanisms underlying malignant transformation in vivo. 22 Skin tumors were induced in Trib3
and Trib3 À / À mice of a mixed C57BL6/J 129/Ola background (see Supplementary Methods for details) by topical treatment with a single dose of 7,12-dimethylbenz[a]anthracene (DMBA) followed by a repeated administration of the phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA) for 20 weeks. After DMBA/TPA challenge, we observed no differences between Trib3 þ / þ and Trib3 À / À mice either in the latency (time from treatment initiation to tumor development) or the size (data not shown) of the skin lesions. However, the frequency of malignant conversion, as determined by the percentage of papillomas that progressed into a more aggressive phenotype (squamous papillomas or squamous papillomas with dysplasia), was significantly higher in Trib3 À / À mice than in their corresponding WT littermates after 20 or 32 weeks of the initiation of the treatment (Figures 3c and d) . Statistically significant differences were not found between Trib3 þ / þ and Trib3 À / À mice in the frequency of 'in situ' or squamous cell carcinomas (Supplementary Figure S3) .
Loss of TRIB3 enhances the phosphorylation of AKT in cancer cells via mTORC2. TRIB3 has been shown to interact with and inhibit AKT, and dysregulation of this kinase has a crucial role in cancer generation and progression. 23 Therefore we next investigated whether the enhanced tumorigenic properties of cells in which TRIB3 has been genetically inhibited rely on an enhanced stimulation of the AKT signalling pathway. In line with this idea, RasV 12 /E1A-transformed Trib3-deficient MEFs, as well as breast carcinoma (BT474) and hepatocellular carcinoma (HepG2) cell lines in which TRIB3 had been knocked down, exhibited an enhanced phosphorylation of AKT (Figure 4a and Supplementary Figure S4a) . Moreover, the increase triggered by the genetic inhibition of Trib3 in the number of À / À cells exhibited higher phosphorylation levels of AKT than those derived from their corresponding WT counterparts (Figure 4b ). Furthermore, cutaneous squamous papillomas from Trib3 À / À mice also showed higher AKT phosphorylation levels than the papillomas derived from their WT littermates (Figure 4c) .
To investigate the mechanism by which the loss of TRIB3 enhances AKT phosphorylation, we analyzed the effect of reexpressing an HA-tagged form of TRIB3 in Trib3-deficient cells. TRIB3 re-expression abolished the enhanced phosphorylation of AKT in Ser 473 but did not modify the phosphorylation of the kinase in Thr 308 ( Figure 4d ). As AKT is phosphorylated on Ser473 by the mTORC2, 24 we next investigated whether the enhanced phosphorylation of AKT on Ser 473 observed in Trib3-deficient cells relied on the dysregulation of the phosphorylation of AKT by mTORC2. In line with this idea, silencing of the mTORC2 protein component rapamycin-insensitive companion of mTOR (RICTOR) or incubation with the mTOR kinase inhibitor torin-1 abolished the enhanced phosphorylation of AKT observed in Ras V12 /E1A-transformed Trib3 trisphosphate. 25 Importantly, studies in mice have demonstrated that PTEN is a haplo-insufficient tumor suppressor, as genetic deletion of one copy of the gene is sufficient to unleash oncogenic responses in different organs. 26 Accordingly, Pten þ / À mice exhibit an enhanced activation of the AKT pathway and spontaneously develop malignant lesions in different tissues, including prostate, adrenal glands and thyroid. 27 Therefore we crossed Trib3 À / À mice with Pten þ / À mice to study whether loss of Trib3 results in an acceleration of these lesions. Eight-month-old animals were killed, and histopathological analyses were performed to analyze the presence of premalignant and malignant lesions in different tissues. Trib3 À / À mice exhibited a very low frequency of lesions in the different tissues analyzed. However,
À / À mice showed a higher frequency of premalignant and malignant lesions than Pten þ / À mice in prostate, adrenal glands and thyroid (Table 1 , Figure 5a and Supplementary Figure S5) . Specifically, 100% of
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Pten +/- Figure S6e) . Furthermore, TRIB3 re-expression restored the ability of serum deprivation to activate the Bim promoter in Trib3 À / À cells, and this effect was abolished when the FOXO-binding sites were mutated in this promoter, thus supporting that TRIB3 participates in the regulation of FOXO activity (Figure 6d) . To investigate the in vivo relevance of our findings, we next analyzed whether genetic inhibition of TRIB3 affects the phosphorylation of FOXO in tumor samples. Knockdown of TRIB3 enhanced FOXO3 phosphorylation in HepG2-andBT474-cell-derived tumor xenografts (Figure 6e ) which occurred in concert with an enhanced expression of a the cell proliferation marker Ki67 in those tumors (Supplementary Figures S6f and g ). Likewise, tumors derived from Ras V12 /E1A-transformed Trib3 À / À cells exhibited a higher phosphorylation of FOXO (Figure 6e ) that was associated with an enhanced Ki67 immunostaining (Supplementary Figure S6h) compared with tumors derived from their corresponding WT counterparts. Furthermore, cutaneous squamous papillomas from Trib3 À / À mice also showed higher FOXO1/3 phosphorylation levels than the papillomas derived from their WT littermates (Figure 6f ).
Loss of Trib3 enhances tumor growth via FOXO inactivation. To study whether the enhanced tumorigenic properties of Trib3
À / À cells relies on FOXO inhibition, we made use of a construct encoding a form of FOXO3 in which the residues phosphorylated by AKT are mutated to Ala (FOXO-A3). Unlike the endogenous form of FOXO3, the FOXO-A3 mutant is located in the nucleus of Trib3 À / À cells (Figure 7a) . Moreover, the expression of FOXO-A3 in Trib3
À / À cells re-established the pattern of FOXO-regulated genes (Supplementary Figure S7a) , as well as the ability of serum deprivation to activate the Bim promoter (Supplementary Figure S7b) . In addition, FOXO-A3 expression abolished the increase in the number of cells and the enhanced clonogenicity characteristic of Trib3 À / À cells (Figures 7b and c) .
Therefore, we next analyzed the effect of the stable expression of the FOXO-A3 mutant on the ability of Ras V12 / E1A-transformed Trib3 À / À MEFs to generate tumor xenografts. As shown in Figure 7d , the growth rate of tumors generated with Foxo-A3-Trib3 À / À cells was strongly reduced in comparison with that of Trib3 À / À cells. Likewise, tumors derived from FOXO-A3-Trib3
À / À cells exhibited a decreased expression of Ki67 when compared with those generated with Trib3 À / À cells (Figure 7e ). Taken together, these observations strongly support that the enhanced tumorigenic properties of Trib3-deficient cells rely -at least in major part -on the enhanced phosphorylation and subsequent inhibition of FOXO transcription factors.
Discussion
Several observations presented in this work show that TRIB3 has a remarkable tumor-suppressive role. For example, (i) oncogenic transformation is facilitated in MEFs derived from Trib3-deficient mice; (ii) genetic inhibition of TRIB3 enhances proliferation, clonogenicity and the ability to generate tumor xenografts of oncogene-transformed MEFs and of several human cancer cell lines; (iii) loss of TRIB3 enhances the frequency of malignant conversion of papillomas generated in mice subjected to DMBA/TPA treatment; and (iv) loss of TRIB3 enhances the incidence of premalignant and malignant lesions in Pten þ / À mice. Our findings demonstrate that the tumor inhibitory role of TRIB3 relies to a large extent on the ability of this pseudokinase to regulate the activity of the AKT pathway. In line with this idea, we found that the genetic inactivation of Trib3 enhances the effect of the deletion of one of the two copies of Pten on the formation of premalignant and malignant lesions in mice. Of note, AKT phosphorylation is increased in hyperplasic adrenal medullas of Pten þ / À Trib3 À / À animals when compared with the same lesion in Pten þ / À mice, thus suggesting that loss of Trib3 produces an increase in the phosphorylation of AKT that contributes to the malignant progression in this tissue. In the same line of reasoning, Trib3 À / À mice subjected to the two-step skin carcinogenesis protocol generated papillomas of a more aggressive phenotype and with higher levels of AKT phosphorylation than papillomas generated in WT littermates. Likewise, tumor xenografts generated with Ras TRIB3 has been previously shown to interact with AKT, 11, 15 although the precise mechanism by which this interaction regulates the activity of the kinase as well as the physiological consequences of this inhibition had not been completely clarified yet. Data presented here show that TRIB3 regulates the phosphorylation of AKT by the mTORC2 complex. Of potential relevance in this context, Sabatini's group has shown that genetic ablation of the mTORC2 component RICTOR affects the phosphorylation of FOXO but not of GSK3 or TSC2, 34 thereby suggesting that phosphorylation of AKT in Ser 473 could be sufficient for the kinase to phosphorylate some of its substrates. In line with this observation and with the notion that TRIB3 participates in the regulation of AKT phosphorylation by mTORC2, we found that genetic inactivation of TRIB3 leads to an enhanced phosphorylation of FOXO and BAD but not of GSK3or PRAS 40. Moreover, we recently found that treatment with D
9
-tetrahydrocannabinol (a compound derived from the plant Cannabis sativa that exerts antitumor effects in mouse models of cancer 14, 15, 35 ) triggers AKT inhibition via an enhanced interaction of TRIB3 with AKT and a subsequent decrease in the interaction of AKT and TRIB3 with the mTORC2 complex. 19 Our data also show that Trib3 interacts more strongly with WT AKT, or with AKT mutants in which Thr 308 and Ser 473 have been mutated to Ala, than with AKT mutants in which these two phosphorylatable residues have been mutated to Asp to mimic the negative charge associated with their phosphorylation (author's unpublished observations). Altogether, these observations cogently support that the interaction with TRIB3 negatively regulates AKT by restricting the access of the kinase to the mTORC2 complex (a schematic of the proposed model is shown in Figure 7f ). Moreover, our findings also show that TRIB3 may contribute to the regulation of AKT selectivity for some of its substrates. Of note, total Akt levels are increased in Trib3 À / À RasV12/E1A-transformed MEFs when compared with their corresponding WT counterparts. Although this effect is much less pronounced than that of TRIB3 genetic inactivation on Akt phosphorylation and does not take place in HepG2 or BT474 cells in which TRIB3 expression was silenced, these observations suggest that TRIB3 may also have a role in the regulation of AKT stability.
Analysis of gene expression profiles of cancer patients from published studies reveals that TRIB3 mRNA levels are downregulated in different tumor types (Supplementary   Tables SII and SIII) . Likewise, high TRIB3 protein levels are associated with good prognosis in breast cancer patients. 36 In addition, TRIB3 is focally deleted in tumors of epithelial origin (tumorscape data set; Supplementary Table SI), thus supporting that loss or downregulation of TRIB3 is an event associated with human cancer. Nevertheless, other studies have found an upregulation of TRIB3 mRNA levels in human cancers. 33, 37 In addition, previous observations by other laboratories indicate that TRIB3 can enhance proliferation and invasiveness of cancer cells in vitro, [31] [32] [33] and a recent study has shown that knockdown of TRIB3 produces a moderate increase in the growth of orthotopic xenografts generated with MDA-231 breast cancer cells. 38 A plausible explanation for the apparently contradictory results obtained here and in those studies could be the existence of differences in the genetic alterations, the degree of differentiation or other relevant phenotypic characteristics in the cell lines used in the various studies. In support of this idea, and as shown in the present study, silencing of TRIB3 produces heterogeneous effects on the tumorigenic properties of different cancer cell lines as it enhances the growth rate of tumors generated with U87MG cells (data not shown), accelerates the onset of HepG2 cell-derived tumors and hastens both processes in tumors generated with BT474 cells. Thus, although the findings presented here cogently support that genetic inhibition of TRIB3 enhances tumorigenesis in several genetic contexts and, specifically, in the presence of activating mutations of Ras or the deletion of one of the copies of Pten, further research should clarify whether inactivation or enhanced expression of TRIB3 may produce a different outcome in a distinct genetic or cellular context. It is worth noting that it has been reported that TRIB3-null animals show upregulation of TRIB1 and TRIB2 in at least some tissues. 39 As TRIB2 is associated with induction of acute myelogenous leukemia 40, 41 and TRIB1 with other malignancies, 42, 43 changes in the levels of the other Tribbles isoforms may also contribute to the phenotype observed in Trib3 À / À animals. In summary, results presented here show that genetic inhibition of TRIB3 increases tumorigenesis in several animal models of cancer and that this effect is due -at least primarily -to the enhanced phosphorylation of AKT by the mTORC2 complex and the subsequent hyperphosphorylation and inactivation of FOXO3. These results may help to set the basis for the development of novel targeted therapies for the management of cancer.
Materials and Methods
A list of the reagents used, primer sequences, antibodies and other materials, together with additional details of all techniques used in this study can be found in Supplementary Methods.
Generation of Trib3
À / À mice. Trib3 þ / À mice (B6;129S5-Trib3Gt(OS-T324148)Lex/Ieg obtained from European Mouse Mutant Archive, EMMA, München, Germany; ID: EM-02346, LEXKO-1947) were back crossed with C57/ BL6 for 10 generations and were then inter-crossed to generate homozygous knockout embryos. This line was developed using the OST324148 OmniBank ES cell line from a sequence tagged gene trap library. 44 Briefly, the gene trap vector included a two expression cassettes (Supplementary Figure S1a) . The first cassette encoded for a splice acceptor site (SA), followed by a fusion protein of beta-galactosidase and neomycin, thereby disrupting transcription of the targeted mRNA. The second cassette encoded for a 'diagnostic marker', followed by a Figure S1e) , and did not produce a truncated version of Trib3 as we had previously proposed in a previous work. 19 Generation of Pten þ / À Trib3 À / À animals. Pten þ / À mice (C57/Bl6/J) were kindly provided by Dr Manuel Serrano (Spanish Cancer Research Center, Madrid, Spain). Characterization of these animals has been previously described. 45 Pten þ / À mice were crossed with Trib3 þ / À mice and the progeny inter-crossed. Animals of the different genotypes were killed at 8 months of age, and histopathological analyses of different organs were performed. All procedures involving animals were performed with the approval of the Complutense University Animal Experimentation Committee in compliance with Spanish and European official regulations.
Genotyping. Tail genomic DNA were isolated using standard procedures. Figure S1 ). Gentotyping of Pten animals has been previously described. 45 Skin chemical carcinogenesis model: animals and treatments.
As pure C57BL6/J mice are refractory to DMBA/ TPA-induced carcinogenesis, Trib3 À / À animals were bred to the DMBA/TPA-sensitive 129/Ola strain. Heterozygous animals from this progeny were inter-crossed to generate the Trib3 þ / þ and Trib3 À / À littermates used in this study (129/SvEvBrd_C57BL6/J mixed genetic background). For the two-stage carcinogenesis experiments, tumors were induced on the shaved dorsal skin of WT (n ¼ 15) and TRB3 KO (n ¼ 20) mice by topical application of a single dose of DMBA (32 mg in 200 ml of acetone), followed by twice-weekly applications of TPA (12.5 mg in 200 ml of acetone) for 20 weeks. The number of tumors (42 mm in diameter) was recorded weekly. TPA treatment was ended after 20 weeks, and animals were left untreated until week 32 after DMBA initiation to allow the development of carcinomas. Tumors were collected at different time points and histologically typed as previously described. At the end of the experiments, mice were killed and tumors or skin were collected. Samples were divided into portions that were 1 frozen in Tissue-Tek (Sakura Finetek Europe, Zoeterwoude, The Netherlands) for immunofluorescence staining, 2 snap-frozen for protein and RNA extraction or 3 fixed in 10% buffered formalin, pH 7.2, for 24-72 h. All the tissues were processed by standard histological techniques for the production of 4-mm thick sections stained with hematoxylin and eosin. Skin slides were studied and classified according to the International Classification of Rodent Tumours (1993). In four cases of animal death, necropsies were performed on all mice within 24 h of death, and samples of cutaneous masses, lung, liver, kidney, spleen, stomach, small and large intestine, adrenal and thyroid gland, reproductive tract and brain were collected and processed the same way.
Cell culture. U87MG (human glioma cell line), BT474 (human breast cancer cells) and HEPG2 cells (human hepatocellular carcinoma cell line) were obtained from the American Culture Collection (Rockville, MD, USA). CarC, CarCR, MSC11B9, MSC11A5, PDV and CarB murine skin carcinoma cell lines (see text and Supplementary Methods for further details) were obtained from Miguel Quintanilla. (CarC-R is a less aggressive epithelial cell line isolated from the fusocellular carcinoma cell line CarC; 21 MSC11B9 (B9) and MSC11A5 (A5) cells were derived, respectively, from the squamous component and the more undifferentiated region of the same carcinoma; 20 PDV cells were derived from a squamous cell carcinoma; and CarB cells from a spindle cell carcinoma).
Trib3 þ / þ and Trib3 À / À MEFs were extracted as previously described 46 and transformed using different retroviral vectors to generate RasV 12 -MEFs, RasV12/ E1A-MEFs, SV40 T-large antigen-MEF and FOXO3/RasV 12 /E1A/-MEFs. Transformed/stably transfected MEFs correspond to a polyclonal mix of at least 20 different selected clones). Cells were cultured in DMEM containing 10% FBS and penicillin/ streptomycin (5 mg/ml). When required, cells were seeded at a density of 5000-10 000 cells/cm 2 and transferred to medium containing 0.5% FBS (except RasV12/E1A-transformed MEFs, which were transferred to media containing 2% FBS) 18 h before performing the different treatments.
Genetic knockdown by small interfering RNA. SMARTpool siRNA duplexes (a combination of four siRNAs into a single pool, which guarantees an efficiency of silencing of at least 75%; Dharmacon, Lafayette, CO, USA) were used to transiently silence the expression of the indicated genes. Controls were transfected with a non-targeted control siRNA. Transfection efficiency was 470% as monitored with a control fluorescent (red) siRNA (siGLO RISC-Free siRNA, Dharmacon).
Infection with TRB3 shRNA-human lentiviral particles. A pool of concentrated transduction-ready viral particles containing three shRNAs targetspecific (or three shRNA non-targeted control) constructs (Santa Cruz Biotechnology, Heidelberg, Germany) was used to infect human cancer cell lines. Clones of stably silenced (or control shRNA transduced) cells were selected. At least 20 different selected clones were pooled for each of the cell lines generated.
Luciferase assays. Cells were transfected with a luciferase reporter constructs containing different promoters along with a Renilla luciferase expression plasmid (pRL-TK) for normalization.
In vivo generation of tumor xenografts. Tumors were induced by subcutaneous injection (Harlan Interfauna Iberica, Barcelona, Spain) of 4 Â 10 6 cells in PBS supplemented with 0.1% glucose in nude mice.
Statistics. Except when otherwise stated, statistical analysis was performed by ANOVA with a post-hoc analysis by the Student-Neuman-Keuls test (paired or unpaired). Differences were considered significant when the P-value was o0.05. Wilcoxon's signed-rank test was used in the analysis of cumulative number of papillomas found in animals subjected to the DMBA/TPA treatment.
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